Floatz logo

Guanfacine

Pathologic Processes

Maimonides Medical CenterSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Pathologic Processes cohort.

Asset / SponsorPhaseRating
5-PYRIMIDINECARBOXAMIDE, 2-((1,1-DIMETHYLETHYL)AMINO)-4-(((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYL)AMINO)-
Celgene
Phase 2CCC
Mrx-2843
Meryx, Inc.
Phase 1CC
METAMIZOLE
Brigham and Women's Hospital
N/AD
VITAMIN D
Umm Al-Qura University
N/AD
Ocrevus
University of South Florida
D

View all 9 →

Same molecule, other indications

Guanfacine is also rated in:

nervous system disorderDormant
BB
Indicative ·
69 / 100
View asset →
disruptive behavior disorderDormant
BB
Indicative ·
69 / 100
View asset →
Self-Injurious BehaviorDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →